How to Conduct a Rigorous Generic Drug Market Analysis: The Complete Practitioner’s Guide
Why Generic Drug Market Analysis Fails — and How to Fix It Most generic drug market analyses make the same […]
REMS Weaponized: How Brand Pharma Turns Safety Programs Into $13.4B Competition Shields
A deep-dive pillar for pharma IP teams, generic market strategists, portfolio managers, and institutional investors tracking ANDA timelines and biosimilar
REMS Weaponized: How Brand Pharma Turns Safety Programs Into $13.4B Competition Shields Read Post »
Machine Learning in Drug Discovery: The Definitive Technical and Strategic Guide for Pharma IP Teams, R&D Leaders, and Institutional Investors
1. Eroom’s Law, the $2.6 Billion Problem, and Why Traditional R&D Has Stopped Working Jack Scannell named Eroom’s Law in
Win the Generic Drug Market: Patents, ANDAs, IP Valuation, and the Tactics That Separate First-Movers from Also-Rans
Executive Summary The global generic drug market sits at an unusual intersection: structural demand that will not shrink, a near-term
Build a Generic Drug Portfolio That Actually Makes Money: The Complete Competitive Intelligence Playbook
The generic pharmaceutical industry has a problem it created for itself. For decades, the dominant growth strategy was volume: file
REMS Abuse: How Brand Pharma Turned Patient Safety Rules Into a $5.4 Billion Competitive Weapon
There is a rule in corporate strategy that says any resource your competitor needs, and that you control, is a
FDA’s Rule of Three: The Complete Playbook for How Generic Competition Kills Drug Prices
Top-Level Key Takeaways 1. What the Rule of Three Actually Is (and What It Isn’t) 1.1 The Economic Premise The
FDA’s Rule of Three: The Complete Playbook for How Generic Competition Kills Drug Prices Read Post »
Generic Drug Partnerships: The Complete IP, ANDA, and Alliance Playbook for Portfolio Managers
1. Why the Generic Market Runs on Partnerships, Not Margins Generics and biosimilars filled 90% of all U.S. prescriptions dispensed
The Role of Green Chemistry in Generic Drug Development: A Sustainable Approach to Medicine
Executive Framing: The Cost Problem That Waste Built {#executive-framing} Generic drugs fill roughly nine out of every ten prescriptions dispensed
